NASDAQ:GTH

Genetron Competitors

$19.95
-0.32 (-1.58 %)
(As of 05/6/2021 12:27 PM ET)
Add
Compare
Today's Range
$19.83
$20.68
50-Day Range
$18.25
$23.64
52-Week Range
$9.03
$31.54
Volume24,298 shs
Average Volume400,597 shs
Market Capitalization$1.77 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Genetron (NASDAQ:GTH) Vs. NVTA, CDNA, BNR, VCYT, FLGT, and CSTL

Should you be buying GTH stock or one of its competitors? Companies in the industry of "medical laboratories" are considered alternatives and competitors to Genetron, including Invitae (NVTA), CareDx (CDNA), Burning Rock Biotech (BNR), Veracyte (VCYT), Fulgent Genetics (FLGT), and Castle Biosciences (CSTL).

Genetron (NASDAQ:GTH) and Invitae (NYSE:NVTA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings.

Profitability

This table compares Genetron and Invitae's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenetronN/AN/AN/A
Invitae-183.50%-81.19%-37.28%

Institutional & Insider Ownership

19.6% of Genetron shares are held by institutional investors. Comparatively, 78.6% of Invitae shares are held by institutional investors. 2.9% of Invitae shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Genetron and Invitae's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genetron$45.68 million38.81$-95,470,000.00N/AN/A
Invitae$216.82 million26.71$-241,960,000.00($2.28)-12.83

Genetron has higher earnings, but lower revenue than Invitae.

Analyst Recommendations

This is a breakdown of recent ratings for Genetron and Invitae, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genetron00203.00
Invitae03402.57

Genetron presently has a consensus price target of $19.50, suggesting a potential downside of 2.26%. Invitae has a consensus price target of $46.1667, suggesting a potential upside of 58.81%. Given Invitae's higher probable upside, analysts clearly believe Invitae is more favorable than Genetron.

Summary

Genetron beats Invitae on 6 of the 11 factors compared between the two stocks.

CareDx (NASDAQ:CDNA) and Genetron (NASDAQ:GTH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Analyst Ratings

This is a summary of current ratings and price targets for CareDx and Genetron, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CareDx01413.00
Genetron00203.00

CareDx currently has a consensus target price of $75.6667, indicating a potential upside of 4.01%. Genetron has a consensus target price of $19.50, indicating a potential downside of 2.26%. Given CareDx's higher probable upside, research analysts plainly believe CareDx is more favorable than Genetron.

Valuation & Earnings

This table compares CareDx and Genetron's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CareDx$127.07 million29.80$-21,970,000.00($0.52)-139.90
Genetron$45.68 million38.81$-95,470,000.00N/AN/A

CareDx has higher revenue and earnings than Genetron.

Institutional and Insider Ownership

19.6% of Genetron shares are owned by institutional investors. 3.1% of CareDx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares CareDx and Genetron's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CareDx-11.79%-10.95%-7.94%
GenetronN/AN/AN/A

Summary

CareDx beats Genetron on 6 of the 11 factors compared between the two stocks.

Genetron (NASDAQ:GTH) and Burning Rock Biotech (NASDAQ:BNR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.

Profitability

This table compares Genetron and Burning Rock Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenetronN/AN/AN/A
Burning Rock BiotechN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Genetron and Burning Rock Biotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genetron00203.00
Burning Rock Biotech00303.00

Genetron currently has a consensus price target of $19.50, indicating a potential downside of 2.26%. Burning Rock Biotech has a consensus price target of $32.30, indicating a potential upside of 12.90%. Given Burning Rock Biotech's higher probable upside, analysts plainly believe Burning Rock Biotech is more favorable than Genetron.

Institutional & Insider Ownership

19.6% of Genetron shares are held by institutional investors. Comparatively, 15.8% of Burning Rock Biotech shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Genetron and Burning Rock Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genetron$45.68 million38.81$-95,470,000.00N/AN/A
Burning Rock BiotechN/AN/AN/AN/AN/A

Burning Rock Biotech has lower revenue, but higher earnings than Genetron.

Veracyte (NASDAQ:VCYT) and Genetron (NASDAQ:GTH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Valuation & Earnings

This table compares Veracyte and Genetron's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$120.37 million23.64$-12,600,000.00($0.27)-156.74
Genetron$45.68 million38.81$-95,470,000.00N/AN/A

Veracyte has higher revenue and earnings than Genetron.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Veracyte and Genetron, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Veracyte11602.63
Genetron00203.00

Veracyte currently has a consensus target price of $64.7143, indicating a potential upside of 52.92%. Genetron has a consensus target price of $19.50, indicating a potential downside of 2.26%. Given Veracyte's higher possible upside, equities research analysts plainly believe Veracyte is more favorable than Genetron.

Profitability

This table compares Veracyte and Genetron's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Veracyte-30.46%-12.27%-10.95%
GenetronN/AN/AN/A

Institutional & Insider Ownership

19.6% of Genetron shares are held by institutional investors. 8.3% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Genetron beats Veracyte on 6 of the 11 factors compared between the two stocks.

Fulgent Genetics (NASDAQ:FLGT) and Genetron (NASDAQ:GTH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Analyst Ratings

This is a breakdown of current ratings for Fulgent Genetics and Genetron, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fulgent Genetics12202.20
Genetron00203.00

Fulgent Genetics presently has a consensus price target of $74.40, suggesting a potential upside of 7.22%. Genetron has a consensus price target of $19.50, suggesting a potential downside of 2.26%. Given Fulgent Genetics' higher probable upside, equities analysts clearly believe Fulgent Genetics is more favorable than Genetron.

Institutional and Insider Ownership

33.4% of Fulgent Genetics shares are held by institutional investors. Comparatively, 19.6% of Genetron shares are held by institutional investors. 45.0% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Fulgent Genetics and Genetron's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fulgent Genetics35.31%43.81%36.82%
GenetronN/AN/AN/A

Earnings & Valuation

This table compares Fulgent Genetics and Genetron's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulgent Genetics$32.53 million62.11$-410,000.00$0.023,485.00
Genetron$45.68 million38.81$-95,470,000.00N/AN/A

Fulgent Genetics has higher earnings, but lower revenue than Genetron.

Summary

Fulgent Genetics beats Genetron on 8 of the 10 factors compared between the two stocks.

Genetron (NASDAQ:GTH) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Profitability

This table compares Genetron and Castle Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenetronN/AN/AN/A
Castle Biosciences-5.30%-2.69%-2.05%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Genetron and Castle Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genetron00203.00
Castle Biosciences00603.00

Genetron currently has a consensus price target of $19.50, suggesting a potential downside of 2.26%. Castle Biosciences has a consensus price target of $85.00, suggesting a potential upside of 48.21%. Given Castle Biosciences' higher possible upside, analysts plainly believe Castle Biosciences is more favorable than Genetron.

Earnings and Valuation

This table compares Genetron and Castle Biosciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genetron$45.68 million38.81$-95,470,000.00N/AN/A
Castle Biosciences$51.87 million27.70$5.28 million($0.81)-70.80

Castle Biosciences has higher revenue and earnings than Genetron.

Insider and Institutional Ownership

19.6% of Genetron shares are held by institutional investors. Comparatively, 66.4% of Castle Biosciences shares are held by institutional investors. 39.7% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Castle Biosciences beats Genetron on 6 of the 10 factors compared between the two stocks.


Genetron Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Invitae logo
NVTA
Invitae
1.6$29.26-6.7%$6.18 billion$216.82 million-7.52Earnings Announcement
Analyst Report
News Coverage
CareDx logo
CDNA
CareDx
1.0$72.75-0.6%$3.81 billion$127.07 million-158.15Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
News Coverage
BNR
Burning Rock Biotech
1.1$28.61-1.1%$3.02 billionN/A0.00Gap Down
Veracyte logo
VCYT
Veracyte
1.4$42.32-3.2%$2.94 billion$120.37 million-61.33Upcoming Earnings
Insider Selling
Fulgent Genetics logo
FLGT
Fulgent Genetics
1.4$69.70-3.1%$2.08 billion$32.53 million34.50Analyst Upgrade
Castle Biosciences logo
CSTL
Castle Biosciences
1.9$57.35-8.6%$1.56 billion$51.87 million-337.33Upcoming Earnings
Analyst Report
RadNet logo
RDNT
RadNet
1.3$22.46-0.1%$1.18 billion$1.15 billion-106.95Upcoming Earnings
Analyst Upgrade
Increase in Short Interest
Renalytix AI logo
RNLX
Renalytix AI
0.7$29.79-1.2%$1.09 billionN/A-186.19Analyst Upgrade
Gap Down
DermTech logo
DMTK
DermTech
1.6$34.00-6.5%$1.05 billion$3.36 million-20.12Upcoming Earnings
Analyst Report
Insider Selling
Personalis logo
PSNL
Personalis
1.6$22.11-4.8%$920.92 million$65.21 million-20.86Earnings Announcement
Analyst Report
News Coverage
Gap Up
Celcuity logo
CELC
Celcuity
1.0$26.50-3.3%$336.32 millionN/A-31.18Analyst Upgrade
Exagen logo
XGN
Exagen
1.7$15.27-1.5%$196.39 million$40.39 million-1.24Upcoming Earnings
Centogene logo
CNTG
Centogene
1.2$9.76-0.1%$193.65 million$54.64 million-6.68News Coverage
Progenity logo
PROG
Progenity
1.8$2.86-8.0%$186.46 millionN/A0.00News Coverage
Gap Down
Enzo Biochem logo
ENZ
Enzo Biochem
0.7$2.79-3.9%$139.86 million$76.02 million-6.49
OpGen logo
OPGN
OpGen
1.3$2.26-7.1%$92.60 million$3.50 million-1.11Gap Down
Biocept logo
BIOC
Biocept
1.2$4.45-2.2%$60.98 million$5.53 million-1.10Upcoming Earnings
AnPac Bio-Medical Science logo
ANPC
AnPac Bio-Medical Science
0.7$4.99-0.0%$55.89 million$1.56 million-3.08
Psychemedics logo
PMD
Psychemedics
0.8$6.75-0.4%$37.37 million$37.68 million-9.78Upcoming Earnings
AMS
American Shared Hospital Services
0.1$3.23-9.9%$20.59 million$20.60 million-32.30News Coverage
Gap Up
This page was last updated on 5/6/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.